Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats

다국어 초록 (Multilingual Abstract)

Risedronate is widely used clinically to treatosteoporosis, Paget’s disease, hypercalcemia, bone metastasis,and multiple myeloma. However, its oral efficacy isrestricted due to its low bioavailability and severe gastrointestinaladverse effects. This study was designed toevaluate the effect of deoxycholic acid derivatives on thepermeability and oral bioavailability of risedronate byincreasing its lipophilicity and affinity to bile transporters.
We synthesized two bile acid derivatives, Na-deoxycholyl-L-lysyl-methylester (DCK) and Na-deoxycholyl-L-lysylhydroxide(HDCK) as oral absorption enhancers. Afterionic complex formation with the bile acid derivatives, thecomplexes were characterized by powder X-ray diffraction.
Their artificial membrane permeabilities and bioavailabilitiesin rats were investigated in comparison with purerisedronate. Complex formation with DCK or HDCKdemonstrated that risedronate existed in an amorphousform in the complex. A physical complex of risedronatewith DCK enhanced the apparent membrane permeability of risedronate significantly but pure risedronate was notpermeable. An in vivo study revealed that the Cmax andAUClast of risedronate/DCK (1:2) complex were 1.92- and2.64-fold higher than those of pure risedronate, respectively.
Thus, the risedronate/DCK complex can improvethe oral absorption of risedronate and patient complianceby reducing dose frequency and adverse reactions.

참고문헌 (Reference)

1 Nam, S.H., "Topically administered risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model" 50 : 149-155, 2012

2 Hamilton, B., "Tolerability and compliance with risedronate in clinical practice" 14 : 259-262, 2003

3 Rodan, G.A., "Therapeutic approaches to bone diseases" 289 : 1508-1514, 2000

4 Kavanagh, K.L., "The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs" 16 : 7829-7834, 2006

5 Hadji, P., "The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures" 23 : 2141-2150, 2012

6 Mitchell, D.Y., "The effect of dosing regimen on the pharmacokinetics of risedronate" 48 : 536-542, 1999

7 Janner, M., "Sodium EDTA enhances intestinal absorption of two bisphosphonates" 49 : 280-2803, 1991

8 Blumentals, W.A., "Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate" 43 : 577-585, 2009

9 Mitchell, D.Y., "Risedronate pharmacokinetics and intra-and inter-subject variability upon single-dose intravenous and oral administration" 18 : 166-170, 2001

10 Mortensen, L., "Risedronate increases bone mass in an early postmenopausal population : two years of treatment plus 1 year of follow-up" 83 : 396-402, 1998

11 Siris, E.S., "Risedronate in the treatment of Paget’s disease of bone : an open label, multicenter study" 13 : 1032-1038, 1998

12 Dunn, C.J., "Risedronate : A review of its pharmacological properties and clinical use in resorptive bone disease" 61 : 685-712, 2001

13 Eastell, R., "Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate" 18 : 1051-1056, 2003

14 Coxon, F.P., "Recent advances in understanding the mechanism of action of bisphosphonates" 6 : 307-312, 2006

15 Lin, J.H., "Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals" 19 : 926-932, 1991

16 Bittner, B., "Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl)amino] caprylate(SNAC)" 67 : 233-241, 2012

17 Lee, S., "Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats" 50 : 1869-1871, 2006

18 Jeon, O.C., "Oral Delivery of Ionic Complex of Ceftriaxone with Bile Acid Derivative in Non-human Primates" SPRINGER/PLENUM PUBLISHERS 30 (30): 959-967, 2013

19 Lin, J.H., "On the absorption of alendronate in rats" 83 : 1741-1746, 1994

20 Luckman, S.P., "Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras" 13 : 581-589, 1998

21 Kimmel, D.B., "Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogencontaining bisphosphonates" 86 : 1022-1033, 2007

22 Reszka, A.A., "Mechanism of action of bisphosphonates" 1 : 45-52, 2003

23 Kim, S.K., "Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance" Pergamon Press 39 (39): 861-870, 2005

24 Park, J.W., "Enhanced oral absorption of ibandronate via complex formation with bile acid derivative" WILEY-BLACKWELL 102 (102): 341-346, 2013

25 Delmas, P.D., "Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis" 42 : 36-42, 2008

26 Ilter, E., "Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis" 9 : 129-134, 2006

27 Eriksen, E.F., "Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis" 31 : 620-625, 2002

28 Mitchell, D.Y., "Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers" 40 : 258-265, 2000

29 Kim, S.K., "Diabetes correction in pancreatectomized canines by orally absorbable insulin-deoxycholate complex" 7 : 708-717, 2010

30 Hounslow, A.M., "Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs" 51 : 4170-4178, 2008

31 Cramer, J.A., "Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis" 21 : 1453-1460, 2005

32 Lin, J.H., "Bisphosphonates : a review of their pharmacokinetic properties" 18 : 75-85, 1996

33 Lambrinoudaki, I., "Bisphosphonates" 1092 : 397-402, 2006

34 Kim, S.K., "Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anticoagulant" 120 : 4-10, 2007

35 Ezra, A., "A peptide prodrug approach for improving bisphosphonate oral absorption" 43 : 3641-3652, 2000

36 McClung, M.R., "A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis : 2-year data" 92 : 59-67, 2013

37 Lee, S., "A new drug carrier, N-alpha-deoxycholyl-L-lysyl-methylester, for enhancing insulin absorption in the intestine" 48 : 405-411, 2005

38 Yates, J., "A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women" 24 : 253-262, 2013